Table 2.
miRNA expression in sepsis-related heart dysfunction.
| Author and Reference | Year of Publication | Sepsis Model | Brief Description of miRNAs in Cardiac Tissue during Sepsis |
|---|---|---|---|
| Wang et al. [54] | 2014 | In vivo | mir-223 was downregulated; downregulation increased inflammation and myocardial injury |
| Liu et al. [56] | 2020 | In vivo | miR-223 was upregulated; upregulation reduced inflammation and apoptosis |
| M’baya-Moutoula et al. [57] | 2018 | In vitro | miR-223 expression regulates NF-κB pathway |
| Xue et al. [58] | 2015 | In vivo | miR-27a was upregulated; upregulation increased inflammation |
| Gao et al. [60] | 2015 | In vivo | miR-146a was upregulated; upregulation reduced inflammation and myocardial injury |
| An et al. [61] | 2018 | In vitro | miR-146a was upregulated; upregulation reduced inflammation and myocardial injury |
| Xie et al. [62] | 2019 | In vivo | miR-146a upregulation reduced inflammation and myocardial injury |
| Wang et al. [63] | 2018 | In vivo | miR-146b was upregulated; upregulation reduced inflammation and myocardial injury |
| Ma et al. [64] | 2016 | In vivo In vitro |
miR-125b was downregulated and its upregulation reduced inflammation and myocardial injury |
| Wei et al. [65] | 2019 | In vitro | miR-150-5p was downregulated and its upregulation reduced inflammation and myocardial injury |
| Zhu et al. [66] | 2020 | In vivo In vitro |
miR-150-5p was downregulated and its upregulation reduced inflammation and myocardial injury |
| Wang et al. [67] | 2016 | In vivo | miR-21-3p was upregulated and its downregulation reduced inflammation and cardiac disfunction |
| Wang et al. [68] | 2016 | In vivo | miR-155 was upregulated and its downregulation reduced inflammation and myocardial injury |
| Zhou et al. [71] | 2017 | In vivo | miR-155 was upregulated and overexpression reduced inflammation and myocardial injury |
| Diao et al.. [69] | 2017 | In vivo | miR-124a was downregulated and its upregulation reduced inflammation and myocardial injury |
| Zheng et al. [70] | 2017 | In vivo | miR-135a was upregulated; upregulation increased myocardial inflammation |
| Ge et al. [72] | 2018 | In vivo | miR-214 was upregulated; upregulation reduced inflammation and myocardial injury |
| Sang et al. [73] | 2020 | In vivo | miR-214-3p was upregulated; upregulation reduced inflammation and myocardial injury |
| Fang et al. [74] | 2018 | In vivo In vitro |
miR-874 was upregulated; upregulation increased inflammation |
| Tang et al. [78] | 2018 | In vitro | miR-93-3p was downregulated and its upregulation reduced inflammation and myocardial injury |
| Yao et al. [79] | 2018 | In vivo In vitro |
miR-25 was downregulated and its upregulation reduced inflammation and myocardial injury |
| Wu et al. [80] | 2018 | In vivo In vitro |
miR-494-3p was downregulated and its upregulation reduced inflammation and myocardial injury |
| Zhang et al. [81] | 2018 | In vivo In vitro |
miR-23b was upregulated; upregulation reduced inflammation and myocardial injury |
| Cao et al. [84] | 2019 | In vivo In vitro |
miR-23b was upregulated; upregulation reduced inflammation and myocardial injury |
| Guo et al. [85] | 2019 | In vivo | miR-495 was downregulated and its upregulation reduced inflammation and myocardial injury |
| Zhu et al. [86] | 2019 | In vivo | miR-98 was downregulated and its upregulation reduced inflammation and myocardial injury |
| Ouyang et al. [87] | 2020 | In vivo | miR-208-5p was upregulated; upregulation increased inflammation and determined myocardial injury |
| Sun et al. [88] | 2020 | In vivo | miR-328 was upregulated; upregulation increased inflammation |
| Zhu et al. [91] | 2020 | In vivo | miR-29a was upregulated; upregulation increased inflammation and determined myocardial injury |
| Song et al. [92] | 2020 | In vivo In vitro |
miR-29a was upregulated; upregulation reduced inflammation and apoptosis |
| Chen et al. [93] | 2020 | In vitro | miR-24 was downregulated; upregulation increased inflammation and determined myocardial injury |
| Sun et al. [94] | 2020 | In vivo In vitro |
miR-192-5p was downregulated; downregulation reduced inflammation and cardiac disfunction |
| Wei et al. [95] | 2020 | In vitro | miR-144-3p was downregulated; upregulation reduced inflammation and myocardial injury |
| Xing et al. [96] | 2020 | In vivo In vitro |
miR-330-5p was downregulated; upregulation reduced inflammation and myocardial injury |
| Han et al. [97] | 2020 | In vivo In vitro |
miR-1-5p was downregulated; downregulation reduced inflammation and cardiac disfunction |
| Li et al. [98] | 2020 | In vivo | miR-29b-3p was downregulated; upregulation reduced inflammation and myocardial injury |
| Xin et al. [99] | 2021 | In vivo In vitro |
miR-101-3p was upregulated; downregulation reduced inflammation and cardiac disfunction |
| Liu et al. [100] | 2021 | In vivo In vitro |
miR-106b-5p was upregulated; upregulation reduced inflammation |
| Zhang et al. [101] | 2021 | In vivo | miR-29c-3p was upregulated; upregulation increased inflammation and determined myocardial injury |
| Yang et al. [102] | 2021 | In vivo In vitro |
miR-499a-5p was downregulated; upregulation reduced inflammation and myocardial injury |